U.S. regulators are likely to approve Merck & Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.
Santa Rosa, US-based healthcare informatics firm AdverseEvents secured $2 million in its Series A funding round led by London, UK-based life science research firm Evaluate Ltd to accelerate its growth.
Investment management firm Blue Ocean invested $5 million in Fort Collins, Colorado-based dental firm St Renatus for the latter's drug application for its needle-free anesthetic.
The row that occurred between 23andMe Inc and the Food and Drug Administration has led to stricter oversight of the genetic testing industry, according to a Bloomberg report.
AstraZeneca acquired Omthera Pharmaceuticals.